Thalia reports early clinical activity for AML RNA therapy miRisten
Thalia Therapeutics has reported initial evidence of biological and clinical activity for its RNA therapeutic miRisten in patients with relapsed or refractory acute myeloid leukaemia (AML), following treatment of nine participants in an ongoing Phase 1 trial.
The interim findings include evidence of target engagement, reductions in leukaemic blast cells and improvements in neutrophil levels. One patient also experienced a transient complete response, with increased neutrophil levels persisting for more than a year.
MiRisten (THAT-001) is an investigational anti-microRNA-126 (anti-miR-126) therapeutic designed to target leukaemia stem cells and their protective bone marrow microenvironment.
The open-label, dose-escalation study is being conducted at City of Hope in California and is evaluating the treatment in patients whose AML has relapsed or proved resistant to previous therapies.
Anti-miR-126 approach demonstrates target engagement
Nine patients have received miRisten, with a median age of 55 and a range of 27 to 79 years. Participants had received a median of four previous lines of treatment.
Two dose levels have been completed, while the third is enrolling its final patients.
Pharmacokinetic testing detected miRisten in patients’ blood following infusion, alongside reductions in miR-126, its intended molecular target. Researchers also observed a preliminary increase in SPRED1, a downstream pharmacodynamic marker.
Together, these findings provide early evidence that the treatment is engaging its intended biological target in humans.
Eight of the nine patients experienced no dose-limiting toxicity during the interim analysis.
The company also reported reductions in leukaemic blast cells and improvements in neutrophil levels following treatment. Neutrophils are white blood cells that play an important role in immune defence, and reduced levels are common in patients with AML.
One patient with relapsed AML and previous neutropenia experienced a transient complete response, accompanied by an increase in neutrophils that has persisted for more than a year. However, the patient developed differentiation syndrome alongside a concurrent infection and discontinued treatment.
The findings are preliminary and do not yet establish whether miRisten can produce sustained remission or improve survival.
Targeting leukaemia stem cells
MiRisten is designed to inhibit microRNA-126 (miR-126), which is involved in maintaining leukaemia stem cell function.
Leukaemia stem cells can contribute to disease persistence and relapse because they may survive conventional treatment and repopulate the cancer.
Research from City of Hope published in the journal Blood in March 2026 investigated the role of miR-126 in maintaining these cells. The study found that inhibiting miR-126 disrupted mitochondrial metabolism and triggered apoptosis in leukaemia stem cells.
The researchers also demonstrated that miRisten enhanced the activity of venetoclax in preclinical AML models, including patient-derived xenografts. Combining miRisten with venetoclax and azacitidine prolonged survival in these models.
These findings provide a scientific rationale for investigating miR-126 inhibition as an approach to AML treatment, although the combination results remain preclinical.
The current Phase 1 study is evaluating miRisten as a monotherapy, rather than testing the venetoclax combination.
Topline Phase 1 results expected in 2027
Thalia expects to complete the current Phase 1 study and report topline results in the first half of 2027. The findings will help determine the next stage of clinical development.
Dr David Solomon, CEO of Thalia Therapeutics, said: “These exciting data provide the first evidence in AML patients that our approach is achieving its intended biological effect and are an important safety and efficacy milestone for miRisten.”
Dr Amanda Blackmon, principal investigator at City of Hope, added: “It is encouraging to see evidence of drug delivery, target engagement and biological activity in relapsed and refractory patients, including improved neutrophil counts and reduced blast levels.”
Thalia acquired Sanmirna Therapeutics in July 2026, bringing miRisten into its development portfolio as part of its transition to a clinical-stage RNA therapeutics company. Its wholly owned US subsidiary holds an exclusive licence from City of Hope to develop and commercialise the candidate.
City of Hope also holds an equity interest in Thalia.
The company is developing miRisten initially for relapsed or refractory AML, with the forthcoming topline results expected to inform its future clinical and regulatory strategy.




